LON:NCYT Novacyt (NCYT) Share Price, News & Analysis GBX 40.82 +0.72 (+1.79%) As of 11:46 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Novacyt Stock (LON:NCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novacyt alerts:Sign Up Key Stats Today's Range 40▼ 4150-Day Range 37.43▼ 44.3052-Week Range 36▼ 100.88Volume59,864 shsAverage Volume133,196 shsMarket Capitalization£28.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com Read More Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Email Address NCYT Stock News HeadlinesNovacyt Updates on Liquidity Agreement and Voting RightsAugust 1, 2025 | tipranks.comNovacyt Updates on Liquidity Agreement and Share TransactionsJuly 1, 2025 | tipranks.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.August 26 at 2:00 AM | Golden Portfolio (Ad)Novacyt’s AGM Approves Key Resolutions for Strategic GrowthJune 20, 2025 | tipranks.comNovacyt Provides Monthly Liquidity Agreement UpdateMay 2, 2025 | tipranks.comNovacyt Provides March 2025 Liquidity Agreement UpdateApril 1, 2025 | tipranks.comNovacyt unit pleads guilty to health and safety chargesMarch 20, 2025 | investing.comUpdate re. Lab 21 HSE ProsecutionMarch 18, 2025 | actusnews.comSee More Headlines NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed this year? Novacyt's stock was trading at GBX 49.30 at the beginning of 2025. Since then, NCYT stock has decreased by 17.2% and is now trading at GBX 40.82. How were Novacyt's earnings last quarter? Novacyt S.A. (LON:NCYT) issued its quarterly earnings data on Wednesday, April, 30th. The company reported ($55.00) earnings per share for the quarter. Novacyt had a negative net margin of 203.06% and a negative trailing twelve-month return on equity of 47.73%. How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Mesa Air Group (MESA), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), Walmart (WMT) and boohoo group (BOO). Company Calendar Last Earnings4/30/2025Today8/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:NCYT CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (54.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£36.80 million Net Margins-203.06% Pretax MarginN/A Return on Equity-47.73% Return on Assets-27.98% Debt Debt-to-Equity Ratio1.92 Current Ratio4.04 Quick Ratio4.46 Sales & Book Value Annual Sales£18.12 million Price / Sales1.56 Cash FlowGBX 70.33 per share Price / Cash Flow0.58 Book ValueGBX 99.62 per share Price / Book0.41Miscellaneous Outstanding Shares69,096,990Free FloatN/AMarket Cap£28.20 million OptionableNot Optionable Beta-1.86 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (LON:NCYT) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.